CGTX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Cognition Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 5, 2026

8-K

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

Oct 22, 2026

8-K

Cognition Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Aug 6, 2026

8-K

Cognition Therapeutics Aligns with FDA on Pivotal Study Design for Zervimesine in DLB Psychosis

Jun 24, 2026

8-K

Cognition Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Cognition Therapeutics Advances Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Jun 4, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Aug 28, 2025

424B5

ATM | Offering amount: $14,583,831 | Amount sold to date: $0 | Float: 55,663,479

Mar 20, 2025

424B5

SHELF OFFERING | Shares amount: 6,571,428 | Share price: $1.75 | Offering amount: $11,499,999.00

Mar 13, 2024

424B5

SHELF PENDING OFFERING | Share price: $1.97

Mar 11, 2024

424B4

SHARE RESALE REGISTRATION | Shares amount: 6,030,532

Jan 8, 2024

424B5

ATM | Offering amount: $40,000,000 | Amount sold to date: $2,400,000 | Float: 24,619,042

Jun 28, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 26, 2026

S-3

December 2025 SHELF and ATM

Dec 18, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 20, 2025

S-8

Registration

Mar 26, 2024

S-3

SHARE RESALE REGISTRATION | Shares amount: 6,030,532 | Share price: $1.88 EFFECTIVE

Dec 29, 2023

S-8

Registration

Mar 23, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Khattar Jack A. (Reporting)

Jun 22, 2026

Monia Brett P (Reporting)

Jun 22, 2026

Wallace Peggy (Reporting)

Jun 22, 2026

RICHSTONE ELLEN B (Reporting)

Jun 22, 2026

BIOS Memory SPV I, LP (Reporting)

Jun 22, 2026

Doyle John Brendan (Reporting)

May 4, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 29, 2025

CORRESP

Form CORRESP - Correspondence

Dec 22, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 9, 2024

CORRESP

Form CORRESP - Correspondence

Jan 4, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jan 3, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 4, 2023

Cognition Therapeutics, Inc. CGTX · SEC Filings